Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760:616–635. doi:10.1016/j.bbagen.2005.12.020
Fritsch K., Mernberger M., Nist A., Stiewe T., Brehm A, Jacob R. Galectin-3 interacts with components of the nuclear ribonucleoprotein complex, BMC Cancer, 2016; 16: 502. doi: 10.1186/s12885-016-2546-0.
Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One, 2013; 8(3): e59616. doi:10.1371/journal. pone.0059616
Vasta GR. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012; 946:21–36. doi: 10.1007/978-1-4614-0106-3_2.
Vasta GR. Roles of galectins in infection, Nat Rev Microbiol 2009; 7(6): 424–438. doi:10.1038/nrmicro2146.
Mey A., Leffler H., Hmama Z., Normier G, Revillard JP. The animal lectin galectin-3 interacts with bacterial mediators of inflammation lipopolysaccharides via two independent sites. J Immunol 1996; 156(4):1572–1577.
Fradin C, Jouault T, Mallet A, et al. Beta-1,2-linked oligoman-nosides inhibit Candida albicans binding to murine macrophage. J Leukoc Biol 1996; 60:81–87. https://doi. org/10.1002/jlb.60.1.81
Kohatsu L, Hsu DK, Jegalian AG, Liu FT, Baum LG. Galectin-3 induces death of Candida species expressing specific beta-1,2-linked mannans. J Immunol 2006; 177:4718–4726. doi:10.4049/jimmunol.177.7.4718
Radosavljevic GD, Pantić JM, Jovanović I, Lukic M, Arsenijević N. The two faces of Galectin-3: Roles in various pathological conditions. Ser J Exp Clin Res 2016; 17:187 - 198. doi: https://doi.org/10.1515/sjecr-2016-0011
Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. In-creased levels of galectin-3 were associated with predia-betes and diabetes: new risk factor? J Endocrinol Invest. 2015; 38(5):527-33. doi: 10.1007/s40618-014-0222-2.
Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation ofgalectin-3 suppresses tumorigenicity of human breast carcinomacells, Clin Cancer Res. 2001; 7:661–668.
Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001; 18:787–792. doi:10.1016/s0304-3835(03)00056-9.
Takenaka Y., Inohara H., Yoshii T, et al. Malignant trans-formation of thyroid follicular cells by galectin-3, Cancer Lett. 2003; 195:111–119
Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis, Apoptosis, 2005; 10:267-275 doi:10.1007/s10495-005-0801-y.
Yu F, Finley Jr RL, Raz A, Kim HR. Galectin-3 trans-locates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation J Biol Chem 2002; 277:15819-15827
Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol, 2004; 24: 4395-4406. doi:10.1128/mcb.24.10.4395-4406.2004
Fukumori T, Takenaka Y, Oka N, et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004; 64:3376-3379. doi:10.1158/0008-5472.CAN-04-0336
Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Can-cer Res 2003; 63:8302-8311
Kouo T, Huang L, Pucsek A, et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacy-toid Dendritic Cells, Cancer Immunol Res 2015; 3(4):412-423. doi: 10.1158/2326-6066.CIR-14-0150.
Fernandez G.C., Ilarregui J.M., Rubel CJ, et al. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alterna-tive MAPK pathways, Glycobiology 2005; 15:519–527. doi:10.1093/glycob/cwi026.
Funasaka T, Raz A, Nangia-Makker P. Nuclear transport of galectin-3 and its therapeutic implications. Semin Cancer Biol. 2014; 27:30-8. doi: 10.1016/j.semcan-cer.2014.03.004.
Saravanan C, Liu FT, Gipson IK, Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J Cell Sci. 2009; 122(20):3684-93. doi: 10.1242/jcs.045674.
Zhao Q., Barclay M., Hilkens J, et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis, Mol Cancer 2010; 9:154. doi: 10.1186/1476-4598-9-154.
Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004; 165(6):1931-41. doi:10.1016/S0002-9440(10)63245-2
Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 2011; 286(34):29913-21. doi: 10.1074/jbc.M111.226423.
Wesley UV, Vemuganti R, Ayvaci ER, Dempsey RJ. Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling. Brain Res. 2013; 1496:1-9. doi: 10.1016/j. brainres.2012.12.008.
Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Commun. 2007; 363(2):336-41. doi:10.1016/j.bbrc.2007.08.179
Jia W, Kidoya H, Yamakawa D, Naito H, Takakura N. Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol. 2013; 182(5):1821-31. doi: 10.1016/j.ajpath.2013.01.017.
Eliaz I, McKee D. Galectin-3 as an oncological biomarker. A review of its possible role in cancer treatment response and disease progression. Nat Med J. 2014; 6(9)
Liu H, D’Ambrosio M, Liao T, et al. N-acetyl-seryl-aspartyllysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol, 2009; 296:H404-412. doi:10.1152/ajp-heart.00747.2008.
Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-infl ammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol, 2008; 294:H1226-H1232. doi: 10.1152/ajp-heart.00305.2007
De Boer, RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the gen-eral population. J Intern Med 2012; 272(1):55-64. doi: 10.1111/j.1365-2796.2011.02476.x
Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coro-nary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem, 2012; 58(1):267-273. doi: 10.1373/clinchem.2011.174359
Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin -3 ,a novel marker of fi brosis , in patients with chronic heart failure: data from the DEAL-HF Study. Clin Res Cardiol. 2010; 99:323-328. doi: 10.1007/s00392-010-0125-y.
. De Boer RA , Lok DJ , Jaarsma T, et al. Predictive value of plasma galectin -3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011; 43:60-68. doi:10.3109/07853890.2010.538080.
De Filippi C., Christenson R., Shah R, et al. Clinical validation of a novel assay for galectin-3 for risk assessment in acutely destabilized heart failure. J Card Fail, 2009; 15:S9. doi: 10.1016/j.cardfail.2009.06.405
Ho JE, Yin X, Levy D, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014: 167:729–734 e721. doi: 10.1016/j.ahj.2014.02.009.
Sonmez О, Ertem FU, Vatankulu MA, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in nonvalvular atrial fibrillation. Med Sci Monit 2014; 20:463–470. doi:10.12659/MSM.890635.
Wu XY, Li SN, Wen SN, et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace. 2015; 17:1541–1547. doi: 10.1093/europace/euv045.
Kornej J., Schmidl J., Ueberham L, et al. Galectin-3 in Pa-tients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation. PLoS ONE. 2015; 10(4):e0123574. doi:10.1371/journal.pone.0123574.
He B., Huang B, Lu Z, He W, Jiang H. Galectin-3: a potential new target for upstream therapy of atrial fibril-lation. Int J Cardiol 2016; 203:1131–1132. doi:10.1016/j. ijcard.2015.09.058.
Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al. New onset atrial fibrillation is associated with elevated galectin-3 levels. Int J Cardiol. 2016: 223, 48-49. doi: 10.1016/j.ijcard.2016.08.172
Clementy N, Piver E, Benhenda N, Bernard A, Pierre B, Simeon E, et al. Galectin-3 in patients undergoing abla-tion of atrial fibrillation . IJC Metab Endocr 2014: http://dx. doi.org/10.1016/j.ijcme.2014.10.003.
Kisheva A. Role of fibrosis and blocking of mineralcor-ticoid receptors in atrial fibrillation. PhD Thesis, 2017, Medical University, Varna, Bulgaria.
Bouguenina H, Salaun D, Mangon A, Muller L, Baudelet E , Camoin L , et al . EB 1 -binding -myomegalin protein complex promotes centrosomal microtubules functions . Proc Natl Acad Sci USA . 2017 ;114 (50):E 10687-E10696. doi: 10.1073/pnas.1705682114.
Clare DK, Magescas J, Piolot T, Dumoux M, Vesque C, Pichard E, et al. Basal foot MTOC organizes pillar MTs required for coordination of beating cilia. Nat Commun 2014;5:4888. doi: 10.1038/ncomms5888.
Albrethsen J, Angeletti RH, Horwitz SB, Yang CP. Proteomics of cancer cell lines resistant to microtubule-stabilizing agents. Mol Cancer Ther 2014;13(1):260-269. doi: 10.1158/1535-7163.MCT-13-0471
Yanev S, Fiore M, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev 2016;27: 59-67.
Natale A, Elayi CS . Colchicine for prevention of post-cardiac procedure atrial fibrillation : Meta -analysis of randomized controlled trials . Int J Car diol 2017; 243:258-262.
Chaldakov GN. Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases. Cell Biol Int 2018; 42(8):1079-1084. doi:10.1002/cbin.10988
Email this article (Login required) 
